アステラス薬：Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV (enfortumab vedotin-ejfv) - 有報キャッチャー

アステラス薬（4503）　Astellas and Seagen Announce Submission of Two Supplemental Biologics License Applications to the U.S. FDA for PADCEV (enfortumab vedotin-ejfv) 2021/02/19

/-

読み込み中…